Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02965716 · ClinicalTrials.gov registry record · Phase 2
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
A Phase 2 study of Unresectable Melanoma and Recurrent Melanoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 20
- Study locations
NCT02965716 is a Phase 2 study of Unresectable Melanoma and Recurrent Melanoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 43 participants, below the 140-participant average among 24 other Unresectable Melanoma trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02965716, a Phase 2 study of Unresectable Melanoma and Recurrent Melanoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and pembrolizumab may work better in treating patients with melanoma by shrinking the tumor.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Talimogene Laherparepvec
Study Locations (20)
Michigan
- Henry Ford Cancer Institute-Downriver - Brownstown
- Henry Ford Macomb Hospital-Clinton Township - Clinton Township
- Henry Ford Hospital - Detroit
- Allegiance Health - Jackson
- Henry Ford West Bloomfield Hospital - West Bloomfield
California
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- Keck Medical Center of USC Pasadena - Pasadena
Ohio
- University of Cincinnati Cancer Center-UC Medical Center - Cincinnati
- Ohio State University Comprehensive Cancer Center - Columbus
- University of Cincinnati Cancer Center-West Chester - West Chester
Alabama
- University of South Alabama Mitchell Cancer Institute - Mobile
Arizona
- CTCA at Western Regional Medical Center - Goodyear
Illinois
- Loyola University Medical Center - Maywood
Indiana
- Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
Kansas
- University of Kansas Hospital-Westwood Cancer Center - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-06-05 |
| Est. Completion | 2026-11-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02965716
The ClinicalTrials.gov registry entry for NCT02965716 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 24 other Unresectable Melanoma trials with a reported enrollment target (69% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Unresectable Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02965716 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Michigan, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT02965716 about?
NCT02965716 is a clinical study titled "Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma". This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways a...
What is the current status of trial NCT02965716?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2018-06-05. Estimated completion is 2026-11-04.
What conditions does trial NCT02965716 study?
This clinical trial studies the following conditions: Unresectable Melanoma, Recurrent Melanoma, Advanced Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IIIC Cutaneous Melanoma AJCC v7.
What interventions are being tested in trial NCT02965716?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Talimogene Laherparepvec (BIOLOGICAL).
Who is sponsoring clinical trial NCT02965716?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02965716 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
RECRUITING · Phase 2
-
Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma
RECRUITING · Phase 2
-
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
RECRUITING · Phase 2
-
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.